Targovax - Småprat 2 (TRVX) 1

[gatfre]

Sendte en mail til meglerhuset angående analyse. Publiserer svaret her når jeg vet noe mere

[1987]

Da tar man et stort lodd her. Synes denne er billig under 9. best in class data​:crossed_fingers:

[1987]

Har hatt en fin reise med next og så element, og fikk rett og slett høydeskrekk der. Da passer dette underprisete papiret godt for en som ikke har tid å sjekke kursen hvert 5. min

[anon79663630]

Jøss, er TRVX fortsatt notert på OSE ? Begynte å lure på om selskapet var tatt av børs. Ble jo dørgende stille i båten.

[oliverv]

Hva mener du? Var jo helt enormt volum i dag …!

[1987]

Kanskje det er lurt å handle når ting er stille og heller selge på litt høyere kurser ;)

[Domboshawa]

Er redd jeg plutselig ble mer langsiktig enn jeg ønsker - hvordan skal de klare å verve og gjennomføre nye pasientgrupper under disse smitteforholdene?

[NidarosEsp1]

NANO har ikke hatt problemer med dette. Så satser på det løser seg her også.

[nordpolen]

(Deleted)

[Krieghoff]

H*n tenker nok veldig mye på de studiene som har planlagt oppstart H1 2022. Det er jo ikke så veldig lenge til og siden det helt sikert er ingen som kommer til å få føflekk kreft i fremtiden fordi alle må holde seg innendørs pga covid19

[NidarosEsp1]

med dette påskeværet så er det vel farlig for solhungrie Nordmenn?

[solskimm]

Kan Sanofi være en aktuell partner for TRVX?
Det var de som kjøpte Kymab, selskapet vårt foreslåtte styremedlem, Sonia Quaratino, kommer fra.

JPM: Sanofi pays $125M to take lead in new checkpoint inhibitor space

[Bianchi]

Upps, kom nær kjøpsknappen👍

[Guny]

Gikk 122 000 i et jafs😳

[BioMed]

Speakers | Tumor Myeloid Microenvironment Directed Therapeutics

[ufo]

Lurer på om TRVX kan søke på patent for abscopal effekt forårsaket av oncos 102.
Skivebom , eller…?

Hvor ble det av PCIB-kompaniet?

[TekBot]

Targovax ASA: Minutes from the Annual General Meeting

The annual general meeting was held on 17 March 2021 at the Company’s offices at
Vollsveien 19, 1366 Lysaker.
All proposals on the agenda were approved.
…

Vis børsmeldingen

Please find minutes of the meeting attached:

2103 minutes
AGM.pdf (https://mb.cision.com/Public/17093/3308155/a780a2da1e3ce0c4.pdf)

---

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

IR enquires:
Kim Sutton Golodetz - LHA Investor Relations (US)
Email: kgolodetz@lhai.com
Phone: +1 212-838-3777

About Targovax

Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax aims to unlock
greater clinical benefits in cancer patients by deploying multifunctional
platforms to target key immune regulators and oncogenic drivers. Targovax’s
focus is to “activate the patient’s immune system to fight cancer”, thus
extending and transforming the lives of cancer patients with targeted
therapeutic cancer immunotherapies. Targovax’s pipeline aims at different cancer
indications, including melanoma, mesothelioma and colorectal cancer. The
products are designed to harness the patient’s own immune system to fight the
cancer, whilst also delivering a favorable safety and tolerability profile.

Targovax’s lead product candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging data in several indications, in monotherapy and in multiple
combination, the next development steps for ONCOS-102 will involve a clinical
trial with registration intent in checkpoint inhibitor refractory melanoma.

Kilde

[TekBot]

Targovax ASA announces new member of the Board

Oslo, Norway, 17 March 2021 - Targovax ASA (OSE: TRVX) announces that the
General meeting has elected seasoned industry expert Sonia Quaratino MD PhD as
new member of the Board of Directors.
…

Vis børsmeldingen

Dr Quaratino is an R&D executive with over 20 years’ experience in clinical
development and immunology research. She is Chief Medical Officer at Kymab, a
clinical-stage biopharmaceutical company recently acquired by Sanofi with a deal
value of approx. USD 1.5bn. She is also the Chair of the Scientific and Clinical
Advisory Board for STipe Therapeutics. Prior to her role at Kymab, Dr Quaratino
held a position as Global Clinical Program Leader - Translational Clinical
Oncology at Novartis, responsible for the clinical development of proprietary
therapeutic antibody programs in immuno-oncology. Prior to this, Dr Quaratino
was Senior Medical Director and Immunology Advisor at Merck Serono, where she
was responsible for the clinical development of various immunomodulators.

Dr Quaratino has an extensive professional background which includes a Medical
Degree and a Doctorate in Hematology-Oncology from the University of Palermo,
Italy and a PhD in Immunology from Imperial College London, UK. For a number of
years, she was a Professor of Immunology at the University of Southampton, a
leading institution for innovative research. During Dr Quaratino’s time in
Southampton her focus was on the pathogenic mechanisms underlying chronic
inflammatory diseases and the interface between autoimmunity and cancer.

Chairman of the Nomination Committee, Mr. Ludvik Sandnes says: “We are very
pleased to have attracted Dr Quaratino as new member of the Board. Dr Quaratino
has an impressive track record in clinical development and immunology research.
In its current phase of development, Targovax requires international competence
on all levels. Dr Quaratino brings both experience from big pharmaceutical
companies as well as a clinical-stage development company. Her research
background is also of great interest to us, as it supplements the knowledge base
in the Board.”

Dr Quaratino is replacing Dr Wheeler. Targovax expresses the company’s gratitude
for the excellent work Dr Wheeler has done as member of the Board over the past
years.

For further information, please contact:
Øystein Soug, CEO
Phone: +47 906 56 525
Email: oystein.soug@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

IR enquires:
Kim Sutton Golodetz - LHA Investor Relations (US)
Email: kgolodetz@lhai.com
Phone: +1 212-838-3777

About Targovax

Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax aims to unlock
greater clinical benefits in cancer patients by deploying multifunctional
platforms to target key immune regulators and oncogenic drivers. Targovax’s
focus is to “activate the patient’s immune system to fight cancer”, thus
extending and transforming the lives of cancer patients with targeted
therapeutic cancer immunotherapies. Targovax’s pipeline aims at different cancer
indications, including melanoma, mesothelioma and colorectal cancer. The
products are designed to harness the patient’s own immune system to fight the
cancer, whilst also delivering a favorable safety and tolerability profile.

Targovax’s lead product candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging data in several indications, in monotherapy and in multiple
combination, the next development steps for ONCOS-102 will involve a clinical
trial with registration intent in checkpoint inhibitor refractory melanoma.

Kilde

[Ramsess]

@TekBot

Sonia Quaratino MD PhD

Sonia Quaratino, MD PhD

[AndreK]

Quaratino til Targovax